Therapy studies using a combination of Betalutin and enzyme specific inhibitors in subcutanoeous xenografted mice

This study will examine the therapeutic potential of enzyme specific inhibitors in combination with Betalutin® for a program under development at Nordic Nanovector. The combination of enzyme specific inhibitors with Betalutin® have not been tested previously invivo, and it is critical to their development that we understand their behavior inside a living animal bearing the human xenograft representative of the cancer they are designed to treat. By demonstrating that the combination of an enzyme specific inhibitor with Betalutin® has the ability to delay tumor growth compared with the proper controls, we can make a scientifically informed decision whether or not to move the combination treatment forward into human clinical trials for Lymphoma. We hypothesize that the combination of selected enzyme specific inhibitors with Betalutin® will either delay growth compared to the controls or shrink tumor size after treatment.

This study requires 660 mice total. The animal's health will be closely monitored. No weight loss or severe discomfort is expected in this animal model, however, any such observations will be recorded in the attached Health score sheet. Animals will be euthanized should they reach any of the defined
humane end points.

All procedures perfromed under this application are in adherence to OUS procedures